fedratinib
Selected indexed studies
- Fedratinib. (, 2012) [PMID:34633785]
- Fedratinib. (, 2006) [PMID:32816422]
- Fedratinib: First Approval. (Drugs, 2019) [PMID:31571162]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fedratinib. (2012) pubmed
- Fedratinib. (2006) pubmed
- Fedratinib: First Approval. (2019) pubmed
- Fedratinib-induced orbital inflammation. (2022) pubmed
- Fedratinib in 2025 and beyond: indications and future applications. (2025) pubmed
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. (2015) pubmed
- Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. (2024) pubmed
- Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. (2021) pubmed
- Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naïve and exposed patients with myelofibrosis. (2022) pubmed
- Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. (2021) pubmed